The price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) closed at $58.50 in the last session, down -3.61% from day before closing price of $60.69. In other words, the price has decreased by -$2.19 from its previous closing price. On the day, 1635150 shares were traded. APLS stock price reached its highest trading level at $60.64 during the session, while it also had its lowest trading level at $57.89.
Ratios:
We take a closer look at APLS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.50 and its Current Ratio is at 3.10. In the meantime, Its Debt-to-Equity ratio is 0.57 whereas as Long-Term Debt/Eq ratio is at 0.54.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on February 05, 2024, Upgraded its rating to Buy and sets its target price to $80 from $68 previously.
On November 09, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $74.Goldman initiated its Buy rating on November 09, 2023, with a $74 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 08 ’24 when Deschatelets Pascal sold 69,107 shares for $62.19 per share. The transaction valued at 4,297,549 led to the insider holds 1,115,983 shares of the business.
Francois Cedric sold 250,000 shares of APLS for $16,028,706 on Mar 01 ’24. The Chief Executive Officer now owns 313,662 shares after completing the transaction at $64.11 per share. On Mar 01 ’24, another insider, Sullivan Timothy Eugene, who serves as the Chief Financial Officer of the company, sold 6,000 shares for $63.22 each. As a result, the insider received 379,340 and left with 93,338 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APLS now has a Market Capitalization of 7.05B and an Enterprise Value of 6.81B. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.79 while its Price-to-Book (P/B) ratio in mrq is 35.96. Its current Enterprise Value per Revenue stands at 17.18 whereas that against EBITDA is -13.76.
Stock Price History:
Over the past 52 weeks, APLS has reached a high of $94.75, while it has fallen to a 52-week low of $19.83. The 50-Day Moving Average of the stock is 65.30, while the 200-Day Moving Average is calculated to be 56.94.
Shares Statistics:
According to the various share statistics, APLS traded on average about 1.98M shares per day over the past 3-months and 1.59M shares per day over the past 10 days. A total of 119.56M shares are outstanding, with a floating share count of 98.80M. Insiders hold about 18.06% of the company’s shares, while institutions hold 91.91% stake in the company. Shares short for APLS as of Feb 29, 2024 were 10.06M with a Short Ratio of 5.09, compared to 10.67M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.35% and a Short% of Float of 9.69%.
Earnings Estimates
The company has 11 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.54 for the current quarter, with a high estimate of -$0.28 and a low estimate of -$0.88, while EPS last year was -$1.56. The consensus estimate for the next quarter is -$0.37, with high estimates of $0.09 and low estimates of -$0.6.
Analysts are recommending an EPS of between $0.46 and -$2.23 for the fiscal current year, implying an average EPS of -$1.18. EPS for the following year is $1.2, with 11 analysts recommending between $2.28 and $0.13.
Revenue Estimates
According to 12 analysts, the current quarter’s revenue is expected to be $161.51M. It ranges from a high estimate of $178.58M to a low estimate of $130.45M. As of the current estimate, Apellis Pharmaceuticals Inc’s year-ago sales were $44.85M, an estimated increase of 260.10% from the year-ago figure. For the next quarter, 12 analysts are estimating revenue of $188.52M, an increase of 168.40% less than the figure of $260.10% in the same quarter last year. There is a high estimate of $228.28M for the next quarter, whereas the lowest estimate is $161.39M.
A total of 13 analysts have provided revenue estimates for APLS’s current fiscal year. The highest revenue estimate was $919.78M, while the lowest revenue estimate was $712.95M, resulting in an average revenue estimate of $798.6M. In the same quarter a year ago, actual revenue was $396.59M, up 101.40% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $1.18B in the next fiscal year. The high estimate is $1.57B and the low estimate is $946.04M. The average revenue growth estimate for next year is up 48.00% from the average revenue estimate for this year.
